Estonia

BMI View: with a few exceptions, the attractiveness of Central And Eastern European (CEE) pharmaceutical markets has remained relatively stable in our Q312 Risk/Reward Ratings (RRRs)... 2012-04-05

BMI View: Estonia's pharmaceutical market will remain of marginal interest to multinationals given its small population and a modest growth outlook. Nevertheless, Estonia's proximity... 2012-03-08

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets... 2011-10-12

BMI View: The key drawback to investment in Estonia's drug market is its small size and moderate-to-weak outlook for growth. However, compared to its Baltic peers, Estonia's drug market... 2011-03-25

BMI View: The economies of Lithuania, Estonia and Latvia were among the worst hit in Europe during the global economic crisis of 2007-2010 and the region's drug markets have not been... 2011-03-08

BMI View: The availability of a highly educated scientific workforce is of vital importance to drugmakers seeking to either outsource or transfer manufacturing and research and development... 2011-02-24

BMI View: Despite Krka reporting relatively strong financial results in first nine months of 2010, BMI believes frequent temporary bans and continuous allegations of patent infringements... 2011-01-20